XML 85 R75.htm IDEA: XBRL DOCUMENT v3.22.1
Share-Based Compensation - Stock Options (Details)
3 Months Ended 17 Months Ended 38 Months Ended 122 Months Ended
Mar. 31, 2022
USD ($)
$ / shares
shares
Mar. 31, 2022
USD ($)
$ / shares
shares
Mar. 31, 2022
USD ($)
$ / shares
shares
Mar. 31, 2022
USD ($)
$ / shares
shares
Additional disclosures        
Intrinsic value of stock option shares exercised | $ $ 418,000      
2004 plan        
Additional disclosures        
Granted (in shares)       0
2012 plan        
Additional disclosures        
Granted (in shares)     0  
2019 plan        
Additional disclosures        
Granted (in shares)   0    
2020 plan        
Share-Based Compensation        
Number of shares registered 2,072,245 2,072,245 2,072,245 2,072,245
Stock Options        
Share-Based Compensation        
Vesting percentage 25.00%      
Vesting period 4 years      
Expiration period 10 years      
Number of shares        
Outstanding at the beginning of the period (in shares) 185,125      
Assumed stock options and warrants from ACBI merger (in shares) 23,410      
Exercised (in shares) (9,703)      
Expired (in shares) (14)      
Outstanding at the end of the period (in shares) 198,818 198,818 198,818 198,818
Exercisable at the end of the period (in shares) 198,818 198,818 198,818 198,818
Weighted-Average Exercise Price        
Outstanding at the beginning of the period (in dollars per share) | $ / shares $ 63.03      
Assumed stock options and warrants from ACBI merger (in dollars per share) | $ / shares 40.73      
Exercised (in dollars per share) | $ / shares 42.25      
Expired (in dollars per share) | $ / shares 33.02      
Outstanding at the end of the period (in dollars per share) | $ / shares 61.42 $ 61.42 $ 61.42 $ 61.42
Exercisable at the end of the period (in dollars per share) | $ / shares $ 61.42 $ 61.42 $ 61.42 $ 61.42
Weighted-Average Remaining Contractual Life        
Outstanding at the end of the period 3 years 9 months 10 days      
Exercisable at the end of the period 3 years 9 months 10 days      
Aggregate Intrinsic Value        
Outstanding at the end of the period | $ $ 4,554,000 $ 4,554,000 $ 4,554,000 $ 4,554,000
Exercisable at the end of the period | $ $ 4,554,000 4,554,000 4,554,000 4,554,000
Additional disclosures        
Granted (in shares) 0      
Total unrecognized compensation cost related to non vested stock option grants | $ $ 0 $ 0 $ 0 $ 0